OmniComm Systems, Inc.'s TrialMaster(TM) Added to Kendle International's Suite of eClinical Solutions in Multi-Year Enterprise Agreement

FORT LAUDERDALE, FL--(Marketwire - September 30, 2009) -

Highlighted Links

Omnicomm Website

OmniComm Systems, Inc. or the "Company" (OTCBB: OMCM), one of the fastest-growing companies in the EDC marketplace, today announced that Kendle, a leading global clinical research organization (CRO), will add OmniComm's TrialMaster EDC solution to its current eClinical offerings in a multi-year enterprise-wide agreement.

"Efficient delivery of high-quality data is critical to Kendle's continued success as a leading provider of clinical data management services," said John Fontenault, Executive Director and Global Head, Clinical Data Management and Technology. "The addition of the TrialMaster EDC solution to our existing offerings supports Kendle's focus on providing our global biopharmaceutical customers with cost-effective access to the best eClinical solutions to accelerate their Phase I through IV clinical trials. The TrialMaster platform offers the right mix of functionality to streamline the study development process and drive efficient study operations."

"We are excited to be working with Kendle to meet the needs of its diverse customer base," said Stephen Johnson, COO of OmniComm Systems. "Kendle is one of the largest and most respected and successful top-tier global CROs with extensive eClinical experience, having conducted more than 250 trials utilizing EDC technologies to expedite the clinical trials process. We look forward to providing them the eClinical solutions and services needed to support their continued delivery of best-in-class clinical development services to their customers."

About Kendle

Kendle International Inc. is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.